IN8bio Shares Are Pulling Back Tuesday: What's Going On?

IN8bio Inc INAB shares are trading lower Tuesday on what appears to be profit taking after the stock rallied 185% on Monday. 

What Happened: IN8bio shares soared on Monday after the company announced new data from the Phase 1 trial of INB-100 showing that patients who received INB-100 treatment exhibited more than 80 times greater gamma-delta T cell expansion.

The stock closed Monday up 185.7% so it's possible Tuesday's pullback is a result of profit taking.

What Else: The company also said it received orphan drug designation from the FDA for two drugs covering a broad range of malignant glioma treatments, including newly diagnosed GBM, a highly aggressive brain cancer.

"Our goal is to achieve our Mission of Cancer Zero by eradicating cancer cells and improving patient outcomes," said William Ho, co-founder and CEO of IN8bio.

"Our novel approach combines engineered, chemo-resistant gamma-delta T cells with standard-of-care treatments to amplify immune signals, maximize tumor killing, and eliminate more cancer cells."

IN8bio said it plans to enroll INB-400 in a Phase 2 trial later this year. The company expects to provide further clinical updates on its pipeline at medical meetings throughout 2023.

See Also: Nasdaq, S&P 500 Futures Slide Ahead Of Microsoft, Alphabet Earnings — Analyst Flags 3 Key Things That Could Impact May Fed Decision

INAB Price Action: IN8bio shares were down 8.33% at $2.75 at the time of writing, according to Benzinga Pro.

Photo: OsloMetX from Pixabay.

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: NewsPenny StocksMoverswhy it's moving
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!